Sunday , December 22 2024
Home / admin (page 1445)

admin

REVENUE INSPECTOR (RI), TULAPADA CIRCLE, NARLA TAHASIL, DIST. KALAHANDI AND ONE PRIVATE PERSON ARRESTED BY VIGILANCE WHILE ACCEPTING BRIBE.

Cuttack,26/03/2021 ( Odisha Samachar ) – Thursday i.e. on 25.3.2021, Sri Thabira Bhoi, Revenue Inspector (RI), Tulapada Circle under Narla Tahasil, Dist. Kalahandi and Sri Baidyanath Sahoo (private person) have been caught by the officers of Vigilance, Koraput Division for demanding and accepting undue advantage (bribe) of Rs.5,000/- (Rupees Five …

Read More »

M1 Reveals Made-to-Measure Bespoke Mobile Plans and Debuts ‘Be’ Campaign’s Inspirational Stories

M1’s made-to-measure Bespoke mobile plans are the next step in the journey to revolutionise Singapore’s telecommunications industry. Reflected in the newly unveiled human-centred stories behind the ‘Be’ campaign, these incredibly flexible mobile plans give customers the freedom to be themselves. SINGAPORE – Media OutReach – 26 March 2021 – Following …

Read More »

M1 Reveals Made-to-Measure Bespoke Mobile Plans and Debuts ‘Be’ Campaign’s Inspirational Stories

M1’s made-to-measure Bespoke mobile plans are the next step in the journey to revolutionise Singapore’s telecommunications industry. Reflected in the newly unveiled human-centred stories behind the ‘Be’ campaign, these incredibly flexible mobile plans give customers the freedom to be themselves. SINGAPORE – Media OutReach – 26 March 2021 – Following …

Read More »

Genor Biopharma Releases Its Annual Results for 2020

Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under Review Clinical development – Three products’ registrational pivotal trails completed (GB226,GB221,GB242), GB491 (CDK 4/6) for 1L and 2L HR+/HER2- breast cancer bridging studies EC approved, …

Read More »

Genor Biopharma Releases Its Annual Results for 2020

Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under Review Clinical development – Three products’ registrational pivotal trails completed (GB226,GB221,GB242), GB491 (CDK 4/6) for 1L and 2L HR+/HER2- breast cancer bridging studies EC approved, …

Read More »